IL-6R / CD126 Antibody ( FITC ) (Cytokine)

IL-6R / CD126 Antibody Datasheet

IL-6R / CD126 Antibody Product Information

• Immunogen: Recombinant Human IL-6R / CD126 protein (Catalog#10398-H08H)
• Reagents: FITC-conjugated mouse monoclonal antibody
• Clone ID: 20
• Ig Type: Mouse IgG1
• Concentration: 5 μl/Test, 0.2 mg/ml
• Formulation: Aqueous solution containing 0.5% BSA and 0.09% sodium azide
• Preparation: This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human IL-6R / CD126 (rh IL-6R / CD126; Catalog#10398-H08H; NP_000556.1; Met 1-Pro 365) and conjugated with FITC under optimum conditions, the unreacted FITC was removed.

IL-6R / CD126 Antibody Usage Guide

• Specificity: Human IL-6R / CD126
• Flow Cytometry:
  

  Flow cytometric analysis of anti-human IL6R (CD126) on Jurkat cells.

  Flow cytometry was performed on a BD FACSCalibur flow cytometry system

  Please refer to www.sinobiological.com/Flow-Cytometry-FACS-Protocols-a-750.html for technical protocols.

• Storage: This antibody is stable for 12 months from date of receipt when stored at 2℃-8℃. Protected from prolonged exposure to light. Do not freeze !
  Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal.

IL-6R / CD126 Antibody Background

Interleukin 6 receptor subunit alpha, also known as IL6R1, CD126, and IL6Ra, is a type I transmembrane cytokine receptor and lacks a tyrosine/kinase domain within the cytoplasmic region, unlike other growth factor receptors. The IL6 receptor is composed of two different subunits, IL6R that binds IL6 with low affinity, and ubiquitously expressed Glycoprotein 130 (gp130) which acts as a common signal-transducing receptor and binds the IL-6/IL-6R complex with high affinity. Interleukin 6 (IL6) is a potent pleiotropic cytokine that regulates cell growth and differentiation of various tissues, and is known particularly for its role in the immune response and acute phase reactions. The soluble form of IL6R arises from proteolytic cleavage of membrane-bound IL6Rα, and acts agonistically by making the IL6 ligand accessible to the signal transducer gp130. Dysregulated production of IL6 and IL6R are implicated in the pathogenesis of several inflammatory diseases and malignancies such as multiple myeloma, rheumatoid arthritis, or osteoporosis. It has been reported that a humanized anti-IL6R monoclonal antibody is a promising agent applicable to the therapeutic approach for IL6 driven diseases.

References

1. Yamasaki, K. et al., 1988, Science. 241: 825-828.
2. Muller-Newen, G. et al., 1998, J. Immunol. 161: 6347-6355.
3. Ancey, C. et al., 2003, J. Biol. Chem. 278: 16968-16972.
4. Yoshio-Hoshino, N. et al., 2007, Cancer. Res. 67: 871-875.
5. Egler, RA. et al., 2008, Clin. Cancer. Res. 14: 7028-7034.